Supplements

Make It Routine: Screening for Cognitive Decline in Primary Care

Only 92.5% of kindergartners received the recommended 2-shot MMR series in 2024-25 and rates were similarly low for DTaP and polio, according to the CDC.

Anna Chodos, MD, MPH;Sydney Jennings

Lecanemab Shows Sustained Benefit at 4 Years in Early Alzheimer Disease: AAIC 2025

Listen to our latest podcast episode to discover how early dementia detection enhances care and quality of life, with actionable strategies for primary care teams to implement now.

The Weekly Dose: Insights on Atopic Dermatitis, Menopause Care, Cancer Screening, and Weight Loss Therapy

Four-year data show lecanemab slows clinical decline in early Alzheimer disease and maintains a consistent safety profile.

Nonmedical Exemptions for Vaccines for Children Should be Eliminated: American Academy of Pediatrics

Insights on an FDA-approved multi-cancer detection test, the impact of obesity pharmacotherapy adherence on weight loss outcomes, and more.

Richard Payerchin

New Option for Chronic Hand Eczema Gets FDA Green Light: Daily Dose

The AAP acknowledges challenges for families but emphasizes mandatory vaccination as crucial for safe school environments.

Childhood Vaccination Rates Fall Again, Exemptions Rise on Cusp of New School Year: CDC Annual Update

Your daily dose of the clinical news you may have missed.

Related Content

Grace Halsey

Make It Routine: Screening for Cognitive Decline in Primary Care

Only 92.5% of kindergartners received the recommended 2-shot MMR series in 2024-25 and rates were similarly low for DTaP and polio, according to the CDC.

Anna Chodos, MD, MPH;Sydney Jennings

Lecanemab Shows Sustained Benefit at 4 Years in Early Alzheimer Disease: AAIC 2025

Listen to our latest podcast episode to discover how early dementia detection enhances care and quality of life, with actionable strategies for primary care teams to implement now.

The Weekly Dose: Insights on Atopic Dermatitis, Menopause Care, Cancer Screening, and Weight Loss Therapy

Four-year data show lecanemab slows clinical decline in early Alzheimer disease and maintains a consistent safety profile.